查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1408269

亞磷醯胺 - 2024 年至 2029 年市場佔有率分析、產業趨勢與統計、成長預測

Phosphoramidite - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2024 - 2029
出版日期: | 出版商: Mordor Intelligence | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

亞磷醯胺市場預計在預測期內複合年成長率為 7.4%

亞磷醯胺-市場-IMG1

主要亮點

  • 當COVID-19大流行開始時，SARS-CoV-2病毒的感染率不斷上升，導致世界各地大多數公司和研究活動停止，導致市場上出現了對亞磷醯胺等基因合成劑的研究。減少了。然而，基因合成儀在基於 mRNA 的 COVID-19 疫苗的研發中發揮了關鍵作用，最終增加了市場對亞磷醯胺的需求。例如，2022 年 1 月，食品藥物管理局第二次核准了 Moderna 的基於 mRNA 的 COVID-19 疫苗 Spikevax。因此，這些發展增加了大流行期間對亞磷醯胺的需求。
  • 亞磷醯胺市場的成長要素包括合成核苷酸在治療學中的應用不斷增加、合成生物學的成長以及用於治療各種慢性疾病的藥物。此外，由於合成生物學具有廣泛的應用範圍，因此世界各國政府都提供研究支援。例如，2022年9月，新南威爾斯州政府宣布將投資超過600萬美元用於新的合成生物學和生物製造開發項目，增加澳大利亞威爾斯州各地的製造和生產設施及設備。 。
  • 此外，產品上市和核准的增加預計將增加對亞磷醯胺合成的需求，推動市場成長。例如，2021年6月，DNAScript推出了Syntax平台和Syntax System，這是一款配備酵素DNA合成（EDS）技術的桌上型核酸印表機。語法系統的建構長度可達 60 個核苷酸，無需額外處理即可在基因組工作流程和分子生物學中使用。該系統允許以創紀錄的速度按需列印 DNA 寡核苷酸，消除了外包亞磷醯胺合成服務可能出現的延遲和缺貨情況。預計此類案例將在預測期內推動市場成長。
  • 然而，長核苷酸序列開發方面的挑戰預計將阻礙市場成長。

亞磷醯胺市場趨勢

DNA 亞磷醯胺預計將在預測期內成長

  • 亞磷醯胺是現代 DNA 合成中使用的標準化學修飾核苷。這些分子能夠透過極其簡單且高效的循環反應在 DNA 鏈順序中付加新鹼基。
  • 次世代定序儀技術在生物標記發現、腫瘤學研究和個人化醫療等多種應用中的使用越來越多，是推動市場成長的關鍵因素。例如，次世代定序技術的迅速出現正在徹底改變基因組學和醫學診斷領域，用基於症候群的面板測序、診斷EXOME測序 (DES) 和基因組序列取代傳統的逐基因方法模型。 （DGS）並改為精確模型。根據美國疾病管制與預防中心 (CDC) 的數據，隨著各國率先對大量人口進行定序，到 2021 年，全球將有超過 6,000 萬人進行基因組定序。事實確實如此。
  • 此外，各種公司正在開發利用亞磷醯胺進行寡核苷酸合成的不同方法，預計將增加製藥和生物技術行業的採用和市場開拓。例如，2022 年 6 月，Amerigo Scientific 推出了一款用於研究應用的超大乾阱（最多可容納 4 公升乙腈溶液）。這些新型 DNA 防潮器可用於在寡核苷酸合成過程中保持無濕環境。這些捕集器可有效乾燥乙腈中的亞磷醯胺溶液、乙腈中的四唑溶液（活化劑溶液）或乾燥乙腈（用於製備亞磷醯胺溶液或活化劑溶液）。
亞磷醯胺-市場-IMG2

預計北美將在預測期內主導市場

  • 政府投資的增加、NGS 研發的進步以及目標疾病盛行率的增加預計將推動北美市場的成長。研究機構、公司和大學增加對次世代定序儀的資助正在促進該地區的市場成長。例如，衛生與公共服務部將於2022 年8 月宣布，將為利用人類轉化/臨床方法（例如基因組學、代謝組學、蛋白質組學）和動物模型的創新研究和結構性出生缺陷研究提供資金。
  • 此外，公司更加重視研發活動，並採取各種業務策略，如產品發布、聯盟、聯合研究和收購，這些也促進了市場的成長。例如，2022 年 5 月，TriLink BioTechnologies 宣布與國防部達成合作協議，其中包括為 TriLink 在加州聖地牙哥擴大核酸生產提供資金。
  • 因此，由於上述新興市場的開拓，預計市場在預測期內將大幅成長。

亞磷醯胺產業概況

亞磷醯胺市場競爭非常激烈，有幾個主要參與者進入該市場。從市場佔有率來看，目前Thermo Fisher Scientific、Biosynth Carbosynth、TriLink BioTechnologies、Bioneer Corporation、Hongene Biotech Corporation等主要公司佔據產業主導地位。

其他福利

  • Excel 格式的市場預測 (ME) 表
  • 3 個月分析師支持

目錄

第1章簡介

  • 研究假設和市場定義
  • 調查範圍

第2章調查方法

第3章執行摘要

第4章市場動態

  • 市場概況
  • 市場促進因素
    • 合成核苷酸在治療上的應用增加
    • 合成生物學的成長
  • 市場抑制因素
    • 開發長核苷酸序列的挑戰
  • 波特五力分析
    • 新進入者的威脅
    • 買家/消費者的議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間敵對關係的強度

第5章市場區隔（市場規模-美元）

  • 按類型
    • DNA亞磷醯胺
    • RNA亞磷醯胺
    • 其他亞磷醯胺
  • 按最終用戶
    • 製藥和生物技術公司
    • 學術/研究機構
    • 其他最終用戶
  • 按地區
    • 北美洲
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 義大利
      • 西班牙
      • 歐洲其他地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳洲
      • 韓國
      • 其他亞太地區
    • 其他

第6章 競爭形勢

  • 公司簡介
    • Thermo Fisher Scientific Inc.
    • Biosynth Ltd
    • TriLink BioTechnologies
    • Bioneer Corporation
    • Hongene Biotech Corporation
    • Tokyo Chemical Industry Pvt. Ltd.
    • Danaher Corporation
    • Creative Biolabs, Inc.
    • PolyOrg, Inc.
    • Lumiprobe Corporation
    • QIAGEN NV
    • BOC Sciences

第7章 市場機會及未來趨勢

簡介目錄
Product Code: 50000918
Phosphoramidite - Market - IMG1

The phosphoramidite market is expected to register a CAGR of 7.4% over the forecast period.

Key Highlights

  • At the start of the COVID-19 pandemic, most businesses and research activities around the world ceased due to the increasing rate of infection from the SARS-CoV-2 virus, which reduced the use and demand of gene synthesizers like phosphoramidite in laboratories in the market. However, gene synthesizers played a crucial role in the research and development of the mRNA-based COVID-19 vaccine, which eventually increased the demand for phosphoramidite in the market. For example, in January 2022, the Food and Drug Administration provided a second approval to the mRNA-based COVID-19 vaccine from Moderna called Spikevax. Therefore, such developments increased the demand for phosphoramidite during the pandemic.
  • The factors responsible for the growth of the phosphoramidite market include increasing synthetic nucleotide applications in therapeutics, growth in synthetic biology, and therapeutics for different chronic diseases. Also, governments of various nations have been providing research support for synthetic biology because of its extensive applications. For instance, in September 2022, the Government of New South Wales announced an investment of over USD 6 million into a new synthetic biology and biomanufacturing development program, which would improve access to manufacturing and production facilities and equipment across the State of Wales, Australia.
  • Furthermore, increasing product launches and approvals are expected to increase the demand for phosphoramidite synthesis, propelling the market growth. For instance, in June 2021, DNA Script launched the Syntax platform with its Syntax System, an Enzymatic DNA Synthesis (EDS) technology-powered benchtop nucleic acid printer. The Syntax System comprises up to 60 nucleotides in length and delivers ready-for-use in d genomics workflows and molecular biology without additional handling. The system enables DNA oligos to be printed on-demand at record speed and without the delays or backorders that can occur with outsourced phosphoramidite synthesis services. Such instances are expected to propel the market's growth over the forecast period.
  • However, challenges in developing long nucleotide sequences are expected to hinder the market's growth.

Phosphoramidite Market Trends

DNA Phosphoramidites is Expected to Witness Growth Over the Forecast Period

  • Phosphoramidites are standard chemical and amodified nucleosides used in modern DNA synthesis. These molecules allow the sequential addition of new bases to the DNA chain in an exquisitely simple and exceptionally efficient cyclic reaction.
  • The increasing use of next-generation sequencing technology in several applications, such as biomarker discovery, oncology studies, and personalized medicine, is the key factor driving the market growth. For instance, the fast emergence of next-generation sequencing technology has revolutionized the field of genomics and medical diagnosis and has changed the traditional model of a gene-by-gene approach to syndrome-based panel sequencing, diagnostic exome sequencing (DES), and diagnostic genome sequencing (DGS), and precision model. According to the Centers for Disease Control and Prevention (CDC), in 2021, it is projected that more than 60 million people will have their genomes sequenced by 2025 worldwide as countries have taken the initiative to sequence large populations.
  • Moreover, various companies are developing different ways to utilize phosphoramidite for oligonucleotide synthesis, which are expected to increase their adoption in the pharmaceutical and biotechnology industry, bolstering market growth. For instance, in June 2022, Amerigo Scientific launched extra large Drying Traps (up to 4 liters of acetonitrile solution) for research applications. These new DNA moisture traps can be used for maintaining moisture-free environments in oligonucleotide synthesis. These traps efficiently dry phosphoramidite solutions in acetonitrile, tetrazole solutions in acetonitrile (activator solutions), or dry acetonitrile (for preparing phosphoramidite solutions or activator solutions).
Phosphoramidite - Market - IMG2

North America is Expected to Dominate the Market Over the Forecast Period

  • The increasing number of investments by the government, advancements in research and development about NGS, and the growing prevalence of target diseases are expected to drive market growth in North America. The rising funding by research institutes, companies, and universities for next-generation sequencing is contributing to the growth of the market in the region. For instance, in August 2022, the Department of Health and Human Services announced funding for innovative research and study of structural birth defects with the use of human translational/clinical approaches (genomics, metabolomics, proteomics, etc.) and animal models.
  • Moreover, the rising focus of companies on research and development activities, as well as the rising adoption of various business strategies such as product launches, partnerships, collaborations, and acquisitions, are also contributing to the market's growth. For instance, In May 2022, TriLink BioTechnologies announced a cooperative agreement with the Department of Defense and included funding for TriLink's expansion in San Diego, California, for nucleic acid production.
  • Thus, the market is expected to witness significant growth over the forecast period due to the above-mentioned developments.

Phosphoramidite Industry Overview

The phosphoramide market is moderately competitive and consists of several major players. In terms of market share, a few of the major players Thermo Fisher Scientific, Biosynth Carbosynth, TriLink BioTechnologies, Bioneer Corporation, Hongene Biotech Corporation and others, are currently dominating the industry.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Synthetic Nucleotide Applications in Therapeutics
    • 4.2.2 Growth in Synthetic Biology
  • 4.3 Market Restraints
    • 4.3.1 Challenges in Developing Long Nucleotide Sequences
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Type
    • 5.1.1 DNA Phosphoramidites
    • 5.1.2 RNA Phosphoramidites
    • 5.1.3 Other Phosphoramidites
  • 5.2 By End-User
    • 5.2.1 Pharmaceutical and Biotechnology Companies
    • 5.2.2 Academic and Research Institutes
    • 5.2.3 Other End-Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Thermo Fisher Scientific Inc.
    • 6.1.2 Biosynth Ltd
    • 6.1.3 TriLink BioTechnologies
    • 6.1.4 Bioneer Corporation
    • 6.1.5 Hongene Biotech Corporation
    • 6.1.6 Tokyo Chemical Industry Pvt. Ltd.
    • 6.1.7 Danaher Corporation
    • 6.1.8 Creative Biolabs, Inc.
    • 6.1.9 PolyOrg, Inc.
    • 6.1.10 Lumiprobe Corporation
    • 6.1.11 QIAGEN N.V.
    • 6.1.12 BOC Sciences

7 MARKET OPPORTUNITIES AND FUTURE TRENDS